Loading...
NPI 1689639544 · Denton, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Healthtrackrx Indiana, Inc is a clinical medical laboratory provider located in Denton, Texas. This profile covers 32 Medicare and 96 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Healthtrackrx Indiana, Inc |
| Address | 1500 Interstate 35 W |
| City | Denton |
| State | TX |
| ZIP | 76207 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 20, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $186M |
| Medicare | $18.7M |
HEALTHTRACKRX INDIANA, INC is operating as a high-volume clinical medical laboratory in Denton, TX (taxonomy: Clinical Medical Laboratory) with an NPI enumerated on 2006-04-20 (~20 years ago). Its code mix is dominated by nucleic acid amplified-probe and multiplex molecular testing (for example 87798, 87481, 87631, U0003 and 87635), indicating a service-line focused on infectious agent detection, respiratory pathogen panels, STI testing, and large-scale SARS–CoV‑2 processing rather than routine anatomic pathology or office-based testing.
Revenue concentration is high for both payers: the provider’s top three Medicare codes account for 49.7% of its Medicare revenue, while the top three Medicaid codes account for 61.5% of its Medicaid revenue. For Medicare the likely revenue leaders driving that concentration include 87798, 87481 and 87631; for Medicaid the concentration is led by 87798, U0003 and 87631, reflecting dependence on a few high-volume molecular assays.
The payer mix is heavily skewed toward Medicaid: Medicare revenue totals $18.7M while Medicaid revenue totals $186M, so Medicaid represents by far the larger share of this provider’s billed public-payer business. This scale difference suggests the lab’s operational capacity and customer base are primarily aligned with Medicaid contracts and volume streams rather than Medicare.
HEALTHTRACKRX shows dominant competitive standing for several codes at the national and state level. On Medicare, 87481 ranks #2 of 1117 providers nationally and is labeled an "extreme outlier," and 87631 ranks #2 of 636 providers nationally (100th percentile); on Medicaid, 87798 ranks #1 of 243 in-state and U0003 ranks #2 of 337 in-state, both described as "extreme outlier" volumes, indicating the provider is a major state-level aggregator for core molecular assays.
The provider’s Medicare top codes include multiple items described as "extreme outlier" or top-percentile volumes: 87798 (22.0% of Medicare revenue; ranks #9 of 1319 nationally, 99th percentile; extreme outlier), 87481 (18.6% of Medicare revenue; ranks #2 of 1117 nationally, 100th percentile; extreme outlier), and 87631 (9.2% of Medicare revenue; ranks #2 of 636 nationally, 100th percentile; extreme outlier). Those positions suggest unusually high per-code Medicare volume relative to national peers for amplified nucleic acid probe testing.
On Medicaid the provider is the clear statewide leader for multiple high-revenue molecular tests: 87798 drives 30.0% of the provider’s Medicaid revenue and ranks #1 in-state (100th percentile; extreme outlier), U0003 drives 22.5% and ranks #2 in-state (100th percentile; extreme outlier), and 87631 contributes 9.0% and ranks #1 in-state (100th percentile; extreme outlier). This pattern indicates that a few large molecular assays, including high-throughput SARS–CoV‑2 testing (U0003) and broad amplified-probe testing (87798), are the core Medicaid revenue engines.
Beyond respiratory and STI molecular assays, the billing mix includes definitive drug testing codes (G0480/G0481/G0483) and multiplex gastrointestinal panels (87507), showing ancillary service lines that generate measurable revenue. For example, Medicaid G0481 produced $2.4M (1.3% of Medicaid revenue) and G0480 produced $1.9M (1.0% of Medicaid revenue) in-state, both ranking at or near the top percentiles locally, which suggests the lab supports both forensic/clinical toxicology and extended molecular panels in its commercial/service offerings.
Multiple individual-code rank labels characterize the provider as a statistical outlier rather than a modest regional lab: many high-volume codes are described as "extreme outlier" or at the 100th percentile in either national (Medicare) or state (Medicaid) comparisons. For contracting or network decisions, that profile signals a centralized, high-throughput service with concentrated molecular testing capacity and a dominant position in the Medicaid molecular testing market in-state.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
32 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 119,800 | $30 | $4.1M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 101,280 | $30 | $3.4M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 12,220 | $140 | $1.7M |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 46,350 | $30 | $1.6M |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 45,330 | $30 | $1.5M |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 44,890 | $30 | $1.5M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 13,310 | $50 | $665.3K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 15,380 | $30 | $523K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 13,100 | $30 | $445.3K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 10,220 | $30 | $347.6K |
Showing 1–10 of 32
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 32 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
32 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87637 | 9 | 70 | 40 | $140 | $404.2K |
| 87798 | 4 | 300 | 790 | $30 | $265.1K |
| K1034 | 51 | 2,490 | 450 | $10 | $117.8K |
| 87631 | 2 | 90 | 50 | $140 | $90.1K |
| 87481 | 1 | 270 | 150 | $30 | $68.8K |
| U0003 | 3 | 60 | 100 | $70 | $64.7K |
| 87634 | 24 | 50 | 30 | $70 | $56.8K |
| 87498 | 5 | 30 | 120 | $30 | $45.9K |
| 87529 | 3 | 60 | 90 | $30 | $43.6K |
| 87541 | 2 | 40 | 140 | $30 | $40.8K |
Showing 1–10 of 32
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
96 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1,471,780 | $40 | $54.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 619,300 | $70 | $40.9M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 347,350 | $50 | $16.3M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 313,290 | $30 | $8.8M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 230,520 | $30 | $6M |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 407,360 | $10 | $5.7M |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 379,870 | $10 | $5.3M |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 342,500 | $20 | $5.1M |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 309,160 | $20 | $4.6M |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 264,210 | $20 | $4M |
Showing 1–10 of 96
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
96 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2 | 340 | 400 | $50 | $553.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 2 | 120 | 340 | $120 | $422K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 20 | 30 | 410 | $70 | $363.5K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 4 | 20 | 180 | $170 | $362.6K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 17 | 160 | 200 | $110 | $323.8K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 9 | 160 | 200 | $280 | $321.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 5 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 5 | 300 | 410 | $20 | $223.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1 | 140 | 180 | $60 | $215.9K |
Showing 1–10 of 96
Other providers in the same ZIP code as Healthtrackrx Indiana, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Sacred Cross Ems | TX | Ambulance | $2.9M | $1.9M |
| Rani Anbarasu | TX | Internal Medicine Physician | $267.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.